Deep Dive

The Deep Dive Digital Magazine offers up-to-date insights on trends in the pharmaceutical and healthcare sectors, presented in a creative and engaging format. Each issue reaches over 40,000 readers.

International, Trade/B2B

English

Magazine

Outlet metrics

Domain Authority

Ranking

Global

#510422

United States

#304072

Health/Biotechnology and Pharmaceuticals

#288

Traffic sources

Monthly visitors

Articles

Roche gets EU okay for chest pain algorithm

2 days ago | pharmaphorum.com | Phil Taylor

News Roche has picked up a CE Mark approval in the EU for an artificial intelligence algorithm that can help doctors decide whether patients presenting with acute chest pain are having a heart attack. The Chest Pain Triage algorithm, developed in collaboration with Universitätsklinikum Heidelberg in Germany, is part of Roche's navify library of medical algorithms designed to make clinical decision-making faster and more tailored to patients. Chest pain is the second most common reason for...
Axtria unveils transformational agentic AI platform for life sciences

2 days ago | pharmaphorum.com | Nicole Raleigh

Axtria Inc., an AI-first data analytics innovator and global provider of cloud software to the life sciences industry, today announced the launch of Axtria InsightsMAx.ai. The next generation agentic platform reimagines how life sciences organisations harness AI through a flexible enterprise-grade infrastructure that accelerates experimentation, deployment, and ROI.
First drug for rare disease APDS cleared for NHS use

2 days ago | pharmaphorum.com | Phil Taylor

Pharming's Joenja has become the first disease-modifying drug that can be used by the NHS to treat activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), an ultra-rare immunodeficiency disorder. The recommendation to back Joenja (leniolisib) throws a lifeline to people with APDS, who suffer severe, recurrent sinopulmonary infections, autoimmune conditions, and inflammatory damage to the small intestine.
Swiss biotech Veraxa vaults to Nasdaq listing with SPAC deal

2 days ago | pharmaphorum.com | Phil Taylor

Zurich-based startup Veraxa Biotech has reached a deal to merge with special purpose acquisition company (SPAC) Voyager, gaining a listing on the Nasdaq that will give it a valuation of around $1.64 billion. The transaction will also add around $263 billion to Veraxa's cash position, which will be used to develop its portfolio of antibody, antibody-drug conjugate (ADC), and bispecific T cell engager (TCE) candidates for cancer.
Has trial result burst BMS' Cobenfy bubble?

2 days ago | pharmaphorum.com | Phil Taylor

Sky-high sales prospects for Bristol Myers Squibb's new schizophrenia treatment Cobenfy may have to be scaled down after a trial designed to expand the label of the recently approved drug failed. Cobenfy (xanomeline tartrate and trospium chloride) was approved last year as a monotherapy for people with schizophrenia, in itself a large potential market, but the new study was hoping to support use as an add-on to standard atypical antipsychotic medications.
Senior FDA resignations gut drug advertising function

2 days ago | pharmaphorum.com | Phil Taylor

Two senior officials at the FDA's drug promotion regulatory office have resigned, leading to speculation that a clampdown on some direct-to-consumer (DTC) advertising of medicines could be on the way. Catherine Gray and Mark Askine, respectively the director and deputy director of the Office of Prescription Drug Promotion (OPDP), have both stepped down effective immediately, according to a report from Politico's AgencyIQ news service.
Driving the drug discovery pipeline: The value of organ-on-a-chip MPS

2 days ago | pharmaphorum.com | Nicole Raleigh

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Tomasz Kostriezewski, CSO at CN Bio, about single organ-on-a-chip technology and multi-organ microphysiological systems (MPS), as well as accelerating drug discovery pipelines with these new alternative methodologies (NAMs). Clinical trial success rates are very low, with up to 95% not succeeding, and a wide range of disease states remains untreated.
Data readout puts J&J's bladder cancer drug back on track

3 days ago | pharmaphorum.com | Phil Taylor

Johnson & Johnson's confidence in its bladder cancer therapy TAR-200 – dented by a negative phase 3 readout last year – seems to be justified. New data from the SunRISe-1 study of TAR-200 in patients with high-risk, non-muscle-invasive bladder cancer (HR-NMIBC) that has not responded to standard BCG treatment build the case for the drug as it heads towards an FDA decision on a marketing application in NMIBC later this year.
Sky Labs' smart ring tops Apple Watch in AFib comparison

3 days ago | pharmaphorum.com | Phil Taylor

News A smart ring developed by South Korean healthtech Sky Labs has outperformed the Apple Watch in a head-to-head comparison of their ability to detect atrial fibrillation (AFib). The study, published in the journal Heart Rhythm O2 and carried out at three clinical centres in the UK, looked at the sensitivity and specificity of the two devices' automatic AFib detection algorithms using single-lead electrocardiograms (SL-ECG) data, which was subsequently interpreted by physicians. Sky Labs'...
Roche joins the pharma firms planning big US investments

3 days ago | pharmaphorum.com | Phil Taylor

News Roche has said it will spend $50 billion on manufacturing and R&D facilities in the US, with a pledge to export more medicines from the US than it imports once the investment programme is completed. The announcement – which comes as the pharma industry is bracing for possible tariffs on the sector from the Trump administration – follows similar announcements from fellow Swiss drugmaker Novartis earlier this month as well as US-headquartered companies Eli Lilly and Johnson & Johnson....